Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features

PURPOSE: Acute myelogenous leukemia (AML) does not have a high cure rate, particularly in patients with poor-risk features. Such patients might benefit from additional therapy in complete remission (CR). Tipifarnib is an oral farnesyltransferase inhibitor with activity in AML. We conducted a phase I...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Karp, Judith E., Smith, B. Douglas, Gojo, Ivana, Lancet, Jeffrey E., Greer, Jacqueline, Klein, Maureen, Morris, Larry, Levis, Mark J., Gore, Steven D., Wright, John J., Garrett-Mayer, Elizabeth
Format: Artigo
Langue:Inglês
Publié: 2008
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3074480/
https://ncbi.nlm.nih.gov/pubmed/18483374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-07-4743
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires